MYOS RENS is evaluating the genotypic characteristics and molecular pathways that contribute to the changes seen in muscle and inflammatory disease states associated with sarcopenia and related disorders.
MYOS RENS takes its responsibility to the environment and the community very seriously. MYOS RENS is committed to being a good corporate citizen and welcomes suggestions on enhancing our contributions in this regard.
Clinical Study will be Completed and its Results Announced in the Second Half of 2018
CEDAR KNOLLS, N.J., Dec. 6, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (Nasdaq: MYOS), has entered into a research agreement with the University of California, Berkeley's Department of Nutritional Sciences & Toxicology. The [...]
Revenue Increased 312% over prior year; Gross Profit Margin of 59%
New Marketing programs with NFL Alumni, IMG College Expected to Strengthen Future Sales
CEDAR KNOLLS, N.J., Nov. 14, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the natural food [...]